Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IMMU-107 (hPAM4), hPAM4, 90Y-hPAM4, anti-mucin antibody
IMMU-107 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| multiple dose levels | EXPERIMENTAL | 1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine. |
| Multi Dose levels | EXPERIMENTAL | different doses of 90YhPAM4 will be given only once. |
| Name | Type | Description |
|---|---|---|
| IMMU-107 (hPAM4) | BIOLOGICAL | 90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks |
| 90Y-hPAM4 | BIOLOGICAL | Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks. |
Inclusion Criteria: * Male or female patients, \>18 years of age, who are able to understand and give written informed consent. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Stage III (locally advanced, unresectable) or Stage IV (metastatic) disease, including patients wh...
Top 20 of 69 competitors
IMMU-107 is an investigational monoclonal antibody that was studied for the treatment of pancreatic cancer. It was evaluated in a Phase 1 clinical trial in combination with gemcitabine in patients with pancreatic cancer. It is not an approved therapy and remains an investigational agent in clinical development.
IMMU-107 is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. The company holds the development program for this monoclonal antibody asset in oncology.
IMMU-107 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
IMMU-107 was evaluated in the Phase 1 trial NCT00603863, titled Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer. The trial enrolled 80 patients in the United States and is completed. It was an uncontrolled study without randomization or blinding.
Yes. IMMU-107 is also known as IMMU-107 (hPAM4). The hPAM4 designation refers to the humanized PAM4 monoclonal antibody component of the agent, which was studied in pancreatic cancer in combination with gemcitabine.